Date: 2015-08-03
Type of information: Services contract
Compound: engineered T cell treatment
Company: Cell Therapy Catapult (UK) Cellular Therapeutics (UK)
Therapeutic area: Cancer - Oncology - Technology - Services
Type agreement: services contract
Action mechanism: cell therapy
Disease: hematological cancers including acute myeloid leukaemia and myelodysplastic syndrome
Details: * On August 3, 2015, The Cell Therapy Catapult has awarded a manufacturing contract to Manchester-based company, Cellular Therapeutics Limited (CTL), to accelerate its clinical programme to develop an engineered T cell treatment for blood cancers such as acute myeloid leukaemia and myelodysplastic syndrome. The contract will run for the next 2-3 years, supporting the current Phase I and II trials which involves the genetic modification of the patient\'s own T cells, so that they may recognise and destroy WT1-expressing cancer cells when infused back into the body. CTL was selected through a rigorous qualification, tender and evaluation process which demonstrated the strength and depth of expertise available in the UK, and it complements the work carried out in collaboration with Imperial College London, University College London and Great Ormond Street Hospital, with scientists led by Prof Hans Stauss and Dr Emma Morris, and originally funded by the charity Leukaemia & Lymphoma Research. Demand for immune cell therapy manufacturing is rapidly expanding globally and this contract puts CTL in a strong position to win more business and bring more cell and gene therapy investment to the UK. This complements the Cell Therapy Catapult’s £55 million large-scale GMP cell therapy manufacturing centre intended for late-stage trials and full commercialisation which is due to open in 2017.
Financial terms:
Latest news:
